Tosaka Chihiro, Tajima Hakuju, Inoue Tadao, Moya Masaaki, Kobayashi Miyuki, Miura Koki, Tada Yuichiro, Masubuchi Tatsuo, Hushimi Chihiro, Kamata Shinetsu
Department of Pharmacy, International University of Health and Welfare, Mita Hospital, Japan.
Gan To Kagaku Ryoho. 2011 Oct;38(10):1647-51.
Chemoradiotherapy for head and neck cancer is associated with a high incidence of severe oral mucositis; an adverse, painful event. Oral mucositis also causes nutritional deficiency by making oral feeding difficult. This may lead to prolongation of hospitalization due to complications caused by malnutrition. However, an effective way to prevent oral mucositis completely, remains to be found. In this study, we evaluated the occurrence of oral mucositis, and nutritional conditions such as hypoalbuminemia, reduction of body weight, and length of hospital stay (days) when the mouth was rinsed using rebamipide solution (R solution), or Poraprezinc-alginate sodium solution (P-A solution) (both considered to be effective for oral mucositis). A mouth rinsed with sodium azulene sulfonate (S solution) was used as a control. The mouth was rinsed out six times per day continuously during chemoradiotherapy. In the study, 31 patients were assigned to rinse their mouths using R solution, 11 patients using PA solution, and 15 patients using S solution (reduction rate of body weight in 14 patients). For the evaluation, the criteria for adverse drug reactions CTCAE (v3. 0) were used. Grade 1 and over, oral mucositis occurred in 48% of the R solution group, 36% of the P-A solution group, and 80% of the S solution group, indicating that the P-A solution group significantly prevented the occurrence of oral mucositis as opposed to the S solution group. A reduction in body weight was observed in 81% of the R solution group, 82% of the P-A solution group, and 79% of the S solution group, indicating a similar weight reduction rate among individual solution groups. Hypoalbuminemia equal to grade 2 or higher occurred in 3% of the R solution group, 18% of the P-A solution group, and 29% of the S solution group, indicating that the R group significantly prevented the occurrence of hypoalbuminemia compared to the S solution group. In addition, the length of hospital stays were 44 ± 8. 0 days for the R solution group, 52 ± 18. 8 days for the P-A solution group, and 61 ± 19. 5 days for the S solution group, indicating that the R solution group significantly shortened the length of hospital stay compared to the S solution group. These results suggested that the use of an R or P-A solution may be effective in preventing oral mucositis and impaired nutrition of those undergoing chemoradiotherapy for head and neck cancer.
头颈部癌的放化疗会导致严重口腔黏膜炎的高发病率,这是一种不良的疼痛事件。口腔黏膜炎还会因口腔进食困难而导致营养缺乏。这可能会因营养不良引起的并发症而导致住院时间延长。然而,完全预防口腔黏膜炎的有效方法仍有待发现。在本研究中,我们评估了使用瑞巴派特溶液(R溶液)或泊拉普利锌 - 海藻酸钠溶液(P - A溶液)(两者都被认为对口腔黏膜炎有效)漱口时口腔黏膜炎的发生情况,以及低白蛋白血症、体重减轻和住院时间(天数)等营养状况。用磺基水杨酸薁(S溶液)漱口作为对照。在放化疗期间,每天连续漱口6次。在该研究中,31例患者被分配使用R溶液漱口,11例患者使用P - A溶液漱口,15例患者使用S溶液漱口(14例患者体重减轻)。对于评估,使用了不良药物反应CTCAE(v3.0)标准。1级及以上口腔黏膜炎在R溶液组中发生率为48%,P - A溶液组中为36%,S溶液组中为80%,这表明与S溶液组相比,P - A溶液组显著预防了口腔黏膜炎的发生。R溶液组中81%的患者体重减轻,P - A溶液组中为82%,S溶液组中为79%,这表明各溶液组之间体重减轻率相似。2级及以上低白蛋白血症在R溶液组中发生率为3%,P - A溶液组中为18%,S溶液组中为29%,这表明与S溶液组相比,R组显著预防了低白蛋白血症的发生。此外,R溶液组的住院时间为44±8.0天,P - A溶液组为52±18.8天,S溶液组为61±19.5天,这表明与S溶液组相比,R溶液组显著缩短了住院时间。这些结果表明,使用R溶液或P - A溶液可能对预防头颈部癌放化疗患者的口腔黏膜炎和营养受损有效。